Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neovasc Inc. T.NVC


Primary Symbol: NVCN

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.


NDAQ:NVCN - Post by User

Comment by biggerron Oct 22, 2018 8:42pm
94 Views
Post# 28852494

RE:Hummm...

RE:Hummm...here is one more good news from today but I don't understand why don't they install Tiara in all mitral problem patients - the open heart surgery is dangerous because you have to go on full anesthesia and you have to wait a long time while Tiara procedure only lasts 15 minutes and you're done
"This live case broadcast reinforced Tiara's potential as a promising treatment option for patients who are unsuitable to receive an open-heart surgical valve replacement," commented Fred Colen, Neovasc's President and Chief Executive Officer
<< Previous
Bullboard Posts
Next >>